Literature DB >> 5628090

Studies in experimental staphylococcal endocarditis in dogs. VI. Treatment with lysostaphin.

L M Goldberg, J M DeFranco, C Watanakunakorn, M Hamburger.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1967        PMID： 5628090

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother (Bethesda)


× No keyword cloud information.
  10 in total

1.  Mechanism and suppression of lysostaphin resistance in oxacillin-resistant Staphylococcus aureus.

Authors:  M W Climo; K Ehlert; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  2001-05       Impact factor: 5.191

2.  Comparison of four methods for determining lysostaphin susceptibility of various strains of Staphylococcus aureus.

Authors:  Caroline M Kusuma; John F Kokai-Kun
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

3.  Lysostaphin treatment of experimental aortic valve endocarditis caused by a Staphylococcus aureus isolate with reduced susceptibility to vancomycin.

Authors:  R L Patron; M W Climo; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1999-07       Impact factor: 5.191

4.  Efficacy and safety of topical lysostaphin treatment of persistent nasal carriage of Staphylococcus aureus.

Authors:  K E Quickel; R Selden; J R Caldwell; N F Nora; W Schaffner
Journal:  Appl Microbiol       Date:  1971-09

5.  Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis.

Authors:  Nandini Kiri; Gordon Archer; Michael W Climo
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

6.  Lysostaphin treatment of experimental methicillin-resistant Staphylococcus aureus aortic valve endocarditis.

Authors:  M W Climo; R L Patron; B P Goldstein; G L Archer
Journal:  Antimicrob Agents Chemother       Date:  1998-06       Impact factor: 5.191

7.  Bioluminescence and 19F magnetic resonance imaging visualize the efficacy of lysostaphin alone and in combination with oxacillin against Staphylococcus aureus in murine thigh and catheter-associated infection models.

Authors:  Tobias Hertlein; Volker Sturm; Udo Lorenz; K Sumathy; Peter Jakob; Knut Ohlsen
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

8.  Evaluation of Topical Lysostaphin as a Novel Treatment for Instrumented Rhesus Macaques (Macaca mulatta) Infected with Methicillin-Resistant Staphylococcus aureus.

Authors:  Christopher E Cheleuitte-Nieves; Leslie L Diaz; Maria Pardos de la Gandara; Alejandra Gonzalez; Winrich A Freiwald; Hermínia M de Lencastre; Alexander Tomasz; Chad W Euler
Journal:  Comp Med       Date:  2020-08-13       Impact factor: 0.982

9.  Design and High Expression of Non-glycosylated Lysostaphins in Pichia pastoris and Their Pharmacodynamic Study.

Authors:  Wenluan Shen; Na Yang; Da Teng; Ya Hao; Xuanxuan Ma; Ruoyu Mao; Jianhua Wang
Journal:  Front Microbiol       Date:  2021-03-18       Impact factor: 5.640

10.  Experimental endocarditis I. Staphylococcal endocarditis in rabbits resulting from placement of a polyethylene catheter in the right side of the heart.

Authors:  P K Garrison; L R Freedman
Journal:  Yale J Biol Med       Date:  1970-06
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.